Researchers from the University of Southern California (USC) have developed a new blood test called OvaPrint that could potentially diagnose ovarian cancer cases at an earlier stage. This test is described as a “cell-free DNA methylation liquid biopsy” and shows high sensitivity and specificity for women with symptoms, with future applications for asymptomatic cases as well. Ovarian cancer, specifically high-grade serous ovarian carcinoma (HGSOC), is often diagnosed at later stages and is the most common and lethal type of ovarian cancer. Currently, the most effective method of identifying a pelvic mass is through surgery and pathological testing. However, there are no effective screening tools available for asymptomatic women. OvaPrint has achieved promising results in distinguishing ovarian cancers from benign masses, surpassing other commercial tests. Further studies and validation are being pursued, with the potential for commercial availability within the next two years. This test has the potential to improve treatment options by guiding surgical approaches based on the malignancy of the mass.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
